Lytgobi is a cancer medicine used to treat adults with cholangiocarcinoma (biliary tract cancer or cancer of the bile ducts) when the cancer cells have an abnormal form of a receptor (target) called FGFR2 on their surface. Lytgobi is used when the cancer has spread to other parts of the body or cannot be removed by surgery and has worsened after previous treatment with at least one cancer medicine. Lytgobi contains the active substance futibatinib.
Therapeutic Indication
### Therapeutic indication Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Therapeutic Area (MeSH)
ATC Code
L01EN04
ATC Item
futibatinib
Pharmacotherapeutic Group
antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Futibatinib | N/A | Futibatinib |
EMA Name
Lytgobi
Medicine Name
Lytgobi
Aliases
N/A